Company / Cash & Equivalents
Yubo International Biotech Ltd Cash & Equivalents History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$8.1K
FY2025
5-year range
$6.4K / $1.4M
FY2021-FY2025
Trend
+14.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 10 years, ranging from $1,000 in FY2017 to $1M in FY2020.
Based on SEC 10-K filings.
$8,062 in FY2025 with a 10-year CAGR of -3.9%.
Improved from $6,359 to $8,062 over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -23.8%
- 5-Year CAGR
- -64.3%
- 10-Year CAGR
- -3.9%
Key checks
Key Insights
- 5-year CAGR of -64.3%, indicating a declining trend.
- In FY2025, cash & equivalents increased 14.9% year-over-year.
- Peak cash & equivalents was recorded in FY2020.
- Lowest cash & equivalents in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score -14.17 (distress zone, below 1.23 threshold)
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $8.1K | +14.9% |
| FY2024 | $7.0K | +10.3% |
| FY2023 | $6.4K | -65.1% |
| FY2022 | $18.2K | -98.7% |
| FY2020 | $1.4M | +109450.2% |
| FY2019 | $1.3K | -36.9% |
| FY2018 | $2.0K | +100.0% |
| FY2017 | $1.0K | -90.9% |
| FY2016 | $11.0K | -8.3% |
| FY2015 | $12.0K | +71.4% |